10th Annual Summit on Biosimilars
January 29 - 30, 2015 - Washington MA USCBI
nyree.kibarian@cbinet.com
Phone:339-298-2100
With five new FDA guidance’s anticipated by year-end, the industry and payers are preparing for the impending changes in the biosimilar market. It is crucial to understand the regulatory and commercial realities to achieve successful product engagement with all stakeholders, specifically payers. Now in its 10th year, CBI’s Annual Summit on Biosimilars places unique focus on the assessment of market access, strategies for effective commercialization and options for interchangeability. Join us to explore the current global climate for biosimilars business, evaluate competition and benchmark with industry peers on how to navigate the changing regulations and landscape of the biosimilars market. Previous Attendee Acclaim: “Only CBI delivers consistent high-quality panel discussions on USA biosimliar pathway policy and legal issues year after year after year!” - Chairman, Harvest Moon Pharmaceuticals “An excellent blend of science, market dynamics, regulatory, law and politics discussed by experts.” – Director, Pfizer